[go: up one dir, main page]

BR9710957A - Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico - Google Patents

Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico

Info

Publication number
BR9710957A
BR9710957A BR9710957-6A BR9710957A BR9710957A BR 9710957 A BR9710957 A BR 9710957A BR 9710957 A BR9710957 A BR 9710957A BR 9710957 A BR9710957 A BR 9710957A
Authority
BR
Brazil
Prior art keywords
atp
mammal
composition
channel inhibitor
inhibitor
Prior art date
Application number
BR9710957-6A
Other languages
English (en)
Inventor
Andrew L Salzman
Csaba Szabo
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BR9710957A publication Critical patent/BR9710957A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<B>COMPOSIçãO COMPREENDENDO UM INIBIDOR DE CANAL K~ ATP~ PARA USO NO TRATAMENTO HEMORRáGICO<D> A presente invenção é dirigida a uma composição farmacologicamente aceitável para inibir ou tratar choque hemorrágico em um mamífero. A composição inclui um inibidor K~ ATP~ e um veículo farmacologicamente aceitável, com o inibidor K~ ATP~ estando presente em uma quantidade suficiente para inibir ou tratar choque hemorrágico no mamífero. A invenção também é dirigida a um método para inibir ou tratar choque hemorrágico em um mamífero. O método inclui administrar ao mamífero uma quantidade de um inibidor de canal K~ ATP~ suficiente para inibir ou tratar choque hemorrágico no mamífero. Em uma forma preferida da invenção, o inibidor de canal K~ ATP~ é selecionado do grupo que consiste em sulfoniluréia, uma guanidina, uma fenotiazina, uma imidazolina, FMB-8 (8-N,N-dietilamino)octila-3,4,5-trimetoxibenzoato, 2,3-butanodiona monoxima, disopiramida, gliquidona, clorpromazina, AMP-NPP, flecainida, MS-551 e suas combinações.
BR9710957-6A 1996-05-03 1997-04-24 Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico BR9710957A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,468 US5856360A (en) 1996-05-03 1996-05-03 Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
PCT/US1997/006790 WO1997041857A1 (en) 1996-05-03 1997-04-24 Composition comprising a katp channel inhibitor for use in the treatment of hemorrhagic shock

Publications (1)

Publication Number Publication Date
BR9710957A true BR9710957A (pt) 2001-10-09

Family

ID=24576682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710957-6A BR9710957A (pt) 1996-05-03 1997-04-24 Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico

Country Status (10)

Country Link
US (1) US5856360A (pt)
EP (1) EP0904078A1 (pt)
JP (1) JP2000512266A (pt)
AU (1) AU2740097A (pt)
BR (1) BR9710957A (pt)
CA (1) CA2251969A1 (pt)
CZ (1) CZ344498A3 (pt)
IL (1) IL126683A0 (pt)
NO (1) NO985116L (pt)
WO (1) WO1997041857A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
DE10129704A1 (de) * 2001-06-22 2003-01-02 Aventis Pharma Gmbh Verwendung von Benzolsulfonyl(thio)harnstoffen in der Behandlung des septischen Schocks
JP4485806B2 (ja) 2002-03-20 2010-06-23 ユニヴァーシティ オブ メリーランド，ボルチモア 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP1802313B1 (en) 2004-09-18 2010-11-03 University of Maryland, Baltimore Therapeutic agents trageting the ncca-atp channel and methods of use thereof
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100056444A1 (en) * 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
CN101932308B (zh) * 2007-12-04 2014-11-05 治疗医药股份有限公司 改良的配制剂和用于冻干的方法及由此提供的冻干物
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
KR20230165363A (ko) 2010-07-19 2023-12-05 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
WO2017062765A1 (en) 2015-10-07 2017-04-13 Remedy Pharmaceuticals, Inc. Methods of treating injuries or conditions related to cns edema
US20170304281A1 (en) * 2016-04-21 2017-10-26 Loyola University Of Chicago Methods of using potassium channel inhibitors (blockers) for fluid resuscitation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0630888B1 (en) * 1993-01-14 2001-04-04 Hiroshi Maeda Imidazoline derivative, production thereof, and blood pressure retentive

Also Published As

Publication number Publication date
IL126683A0 (en) 1999-08-17
US5856360A (en) 1999-01-05
JP2000512266A (ja) 2000-09-19
CZ344498A3 (cs) 1999-04-14
NO985116D0 (no) 1998-11-02
EP0904078A1 (en) 1999-03-31
AU2740097A (en) 1997-11-26
CA2251969A1 (en) 1997-11-13
NO985116L (no) 1998-11-02
WO1997041857A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
BR9710957A (pt) Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico
PT100963A (pt) Composicoes farmaceuticas para aplicacao topica de elevada penetracao atraves da pele que compreendem certos polimeros nao-ionicos especificos
MX9308199A (es) Inhibidores de enzima.
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
PT735890E (pt) Misturas de 2&#39;,3&#39;-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
KR910000169A (ko) 포유류에서 이식 거부를 억제시키는 라파마이신의 용도
MX9205280A (es) Derivados de benzanilida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
MX9205937A (es) Sistema de penetracion incrementada de la piel para surtido topico mejorado de farmacos
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
ES2060064T3 (es) Combinaciones microbicidas sinergicas.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
KR950007868A (ko) 항궤양제 및 헬리코박터·피롤리의 정착저해제
BR9811099A (pt) Inibidores de urocinase
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
ES2123643T3 (es) Composicion y metodo para la eliminacion de oxigeno.
MX9207383A (es) Derivados de 2-imidazolin-5-onas y 2-imidazolin-5-tionas, procedimiento para su preparacion y composiciones fungicidas que los contienen.
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]